A Phase 3 Study of NPC-06 in Patients With Pain Associated With Acute Herpes Zoster
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
To confirm the pain relief effect and the safety of NPC-06 (fosphenytoin sodium hydrate) in
patients with pain associated with acute herpes zoster in a placebo-controlled, double-blind,
parallel-group, comparative manner.